SCHEMBL2153418

SCHEMBL2153418

COc1cnc(C(=O)Nc2ccc(F)c(C3(C(F)F)CNCC(N)=N3)c2)c(N)n1

nearest known ligand 0.75

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 20/20 0.75
CTSD P07339 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2153896 1.00 BACE1 (0.75) BACE1CTSD
SCHEMBL15361835 0.87 BACE1 (0.57) BACE1CTSD
SCHEMBL362674 0.85 BACE1 (1.00) BACE1
SCHEMBL362022 0.85 BACE1 (1.00) BACE1
SCHEMBL2153641 0.82 BACE1 (0.74) BACE1
SCHEMBL2153332 0.82 BACE1 (0.55) BACE1
SCHEMBL2153105 0.82 BACE1 (0.55) BACE1
SCHEMBL2154050 0.82 BACE1 (0.75) BACE1CTSD
SCHEMBL2154463 0.82 BACE1 (0.75) BACE1CTSD
SCHEMBL15678387 0.80 BACE1 (0.90) BACE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011080176-A1 PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2011-07-07 WO claimed
WO-2011080176-A1 PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS NOVARTIS AG (CH) 2011-07-07 WO disclosed